We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
+18.31%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$635M
AUM Growth
-$6.52M
Cap. Flow
-$38.5M
Cap. Flow %
-6.06%
Top 10 Hldgs %
52.93%
Holding
70
New
19
Increased
8
Reduced
12
Closed
25

Top Buys

Rank Stock Value
1
IOVA icon
Iovance Biotherapeutics
IOVA
+$47.3M
2
ENDP
Endo International plc
ENDP
+$17.4M
3
EXAS
Exact Sciences
EXAS
+$14.1M
4
ADMA icon
ADMA Biologics
ADMA
+$12.6M
5
XRAY icon
Dentsply Sirona
XRAY
+$12.3M

Top Sells

Rank Stock Value
1
HRTX icon
Heron Therapeutics
HRTX
+$33.8M
2
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$19.7M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$18.7M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$16M
5
ANGO icon
AngioDynamics
ANGO
+$15.7M

Sector Composition

Rank Sector Weight
1 Healthcare 84.19%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GKOS icon
51
Glaukos
GKOS
$9.02B
– –
-293,900
Closed -$9.06M
MRK icon
52
Merck
MRK
$324B
– –
-137,183
Closed -$7.13M
PCRX icon
53
Pacira BioSciences
PCRX
$1.02B
– –
-166,500
Closed -$5.19M
TPST icon
54
Tempest Therapeutics
TPST
$14.8M
– –
-186
Closed -$442K
VCEL icon
55
Vericel Corp
VCEL
$2.3B
– –
-658,900
Closed -$6.56M
VCYT icon
56
Veracyte
VCYT
$4.52B
– –
-600,658
Closed -$3.34M
NVTA
57
DELISTED
Invitae Corporation
NVTA
– –
-750,000
Closed -$3.52M
PRTK
58
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
– –
-477,607
Closed -$6.21M
NUVA
59
DELISTED
NuVasive, Inc.
NUVA
– –
-258,292
Closed -$13.5M
NTUS
60
DELISTED
Natus Medical Inc
NTUS
– –
-113,526
Closed -$3.82M
GWPH
61
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
– –
-175,030
Closed -$19.7M
VAR
62
DELISTED
Varian Medical Systems, Inc.
VAR
– –
-30,000
Closed -$3.68M
OXFD
63
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
– –
-374,233
Closed -$4.66M
AMAG
64
DELISTED
AMAG Pharmaceuticals
AMAG
– –
-598,800
Closed -$12.1M
TTPH
65
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
– –
-52,432
Closed -$3.22M
PGNX
66
CALL
DELISTED
Progenics Pharmaceuticals Inc
PGNX
– –
-500,000
Closed -$3.73M
CFRX
67
DELISTED
ContraFect Corporation
CFRX
– –
-487
Closed -$633K
HZNP
68
CALL
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-300,000
Closed -$4.26M
IVTY
69
DELISTED
Invuity, Inc
IVTY
– –
-298,800
Closed -$1.15M
1 2
3

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q2 2018 Portfolio in Review

As of Q2 2018, Broadfin Capital held 70 positions worth $635M, down 1% from $642M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Broadfin Capital withdrew a net $38.5M in Q2 2018, closing 25 positions and reducing 12 holdings. Its most notable exit was GW Pharmaceuticals Plc American Depositary Shares, an estimated $19.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, down from 87% a quarter earlier.

Against the trend, Broadfin Capital opened a new position in Endo International plc worth $24.4M.

  • Broadfin Capital's largest Q2 2018 buy was Endo International plc: 2,591,573 shares worth $24.4M.
  • Broadfin Capital added most to Iovance Biotherapeutics in Q2 2018, an estimated $47.3M increase.
  • Broadfin Capital's biggest Q2 2018 reduction was Heron Therapeutics, cutting an estimated $33.8M.
  • Broadfin Capital fully exited GW Pharmaceuticals Plc American Depositary Shares in Q2 2018, selling an estimated $19.7M.
  • Broadfin Capital's ten largest holdings make up 53% of its $635M portfolio in Q2 2018.
  • Broadfin Capital opened 19 new positions and closed 25 in Q2 2018.
  • Broadfin Capital's portfolio value fell 1% quarter-over-quarter to $635M.

Based on Broadfin Capital's 13F filing for Q2 2018, filed 14 Aug 2018.